Sarah Faust

Sarah Faust is a senior commercial leader in the pharmaceutical industry with U.S. and global experience. She has a proven track record of launching and growing multi-million to multi-billion dollar brands spanning the specialty, retail and institutional settings.

Sarah’s recent roles include leading all aspects of marketing at Depomed for the relaunch of Nucynta and Nucynta ER from acquisition, through repositioning, strategy development and oversight of tactical execution for launch. Prior to this, Sarah was Vice President of Sales and Marketing, for the specialty dermatology company, PharmaDerm. Here she managed the strategic refocusing of the Company’s portfolio and resource optimization to drive profitability, launched competitive action plans to defend the Company’s leading brand and led growth strategies to double revenues of another. Before PharmaDerm, Sarah held the position of Senior Vice President of Marketing for the specialty pharmaceutical company King Pharmaceuticals, where she oversaw the launch of the first abuse deterrent opioid, prepared launches for a portfolio of others and drove revenues of the Company’s existing pain and hospital based products. Sarah played a pivotal role in the transition of the PharmaDerm and King businesses following their acquisition by Sandoz and Pfizer respectively. Previously, Sarah led the global marketing team for Lovenox, the world’s leading low molecular weight heparin, where she established deep experience in the surgical and institutional settings.